PROCRITline.com - Provider Resources Introduction

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Introduction

Announcements

Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT^® (Epoetin alfa)

Please see full Prescribing Information, including Boxed WARNINGS, for LEUSTATIN^® (cladribine)

Reimbursement Overview

Oncology Diagnosis Codes

Nephrology Diagnosis Codes

Surgery Diagnosis Codes

Virology Diagnosis Codes

Oncology Toolkit

HELPFUL RESOURCES

Helpful Resources Introduction

Managing a practice is not always easy. Practices need payor information and billing forms. These are some of the tools that you will find in this section. Whether you have an established practice or you've just hung out your shingle, this information will help you and your staff.

CPT codes, descriptions and material only are copyright 2008 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS Restrictions Apply to Government Use.

PROCRIT Announcements

Medicare Physician Fee Schedule Changes for 2009

Medicare Hospital Outpatient Prospective Payment System (OPPS) Changes for 2009

Medicare's Physician Quality Reporting Initiative (PQRI) Continues for 2009

Recovery Audit Contractors (RACs)

Electronic Billing for ESAs

National Drug Codes for Medicaid Claims Submissions

CMS Clarifies Starting Dose Limits for ESA Treatment

PROCRIT Reimbursement - Overview

This PROCRIT Reimbursement - Overview outlines the key points you'll need to know for PROCRIT^® (Epoetin alfa) reimbursement.

Reference Guides to ICD-9-CM Diagnosis Codes

These separate Reference Guides for Oncology, Nephrology, Surgery and Virology contain the ICD-9 codes for PROCRIT.

Oncology Toolkit

This Oncology Toolkit contains examples of the documents that are most often used to prepare a payment claim. You may find them helpful in developing, adding to, or modifying the material you currently use. Click here for a printable version of the Evaluation & Management Progress Note and the Chemotherapy Treatment Notes/Flow Sheet.

Full Prescribing Information, Including Boxed WARNINGS

For the package insert for PROCRIT^® (Epoetin alfa) or for LEUSTATIN^® (cladribine injection) click here:

	PROCRIT Full Prescribing Information, including Boxed WARNINGS
	LEUSTATIN Full Prescribing Information, including Boxed WARNINGS

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.

Boxed WARNINGS: LEUSTATIN^® (cladribine) Injection

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

Please see full Prescribing Information, including Boxed WARNINGS for LEUSTATIN^® (cladribine)